NantHealth (NH) Tops Q4 EPS by 1c

NantHealth (NASDAQ: NH) reported Q4 EPS of ($0.18), $0.01 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $24.08 million versus the consensus estimate of $27.93 million.

“Our GPS Cancer Test continues to gain coverage in both the commercial health insurance and self-employed payor markets, and we are seeking to build adoption for GPS Cancer among oncologists through our ongoing efforts to educate the medical community about the test’s value,” said Patrick Soon-Shiong, M.D., Chief Executive Officer and Chairman of NantHealth.

For earnings history and earnings-related data on NantHealth (NH) click here.

You May Also Be Interested In

• Hasbro (HAS) brand strength sees earnings top expectations
• Capitol Federal Financial (CFFN) Misses Q2 EPS by 1c
• Ribbon Communications (RBBN) Misses Q1 EPS by 2c; offers guidance